Comparative Pharmacology
Head-to-head clinical analysis: CRISABOROLE versus ROFLUMILAST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRISABOROLE versus ROFLUMILAST.
CRISABOROLE vs ROFLUMILAST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Crisaborole is a phosphodiesterase 4 (PDE4) inhibitor. It reduces the production of proinflammatory cytokines by inhibiting PDE4-mediated degradation of cyclic adenosine monophosphate (cAMP), leading to decreased inflammation in the skin.
Selective phosphodiesterase 4 (PDE4) inhibitor; increases intracellular cyclic AMP levels, reducing inflammation and relaxing smooth muscle in the airways.
Intravenous: 0.25 mg/m² over 30 minutes on Days 1, 2, and 8, 9 of a 21-day cycle. Premedicate with antiemetics. For acute promyelocytic leukemia, 0.25 mg/m² on Days 1, 2, 8, 9 of a 28-day cycle.
500 mcg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours (range 3-8 hours) in healthy subjects; no clinically relevant accumulation with once-daily dosing.
Clinical Note
moderateRoflumilast + Budesonide
"Roflumilast may increase the immunosuppressive activities of Budesonide."
Clinical Note
moderateRoflumilast + Prednisolone
"Roflumilast may increase the immunosuppressive activities of Prednisolone."
Clinical Note
moderateRoflumilast + Deflazacort
"Roflumilast may increase the immunosuppressive activities of Deflazacort."
Clinical Note
moderateRoflumilast + Cortisone acetate
Terminal elimination half-life approximately 29-30 hours in COPD patients, allowing once-daily dosing. Steady-state reached in 4-5 days.
Primarily hepatic metabolism (CYP3A4 and CYP2D6) with renal excretion of metabolites: unchanged drug <1% in urine; fecal excretion accounts for approximately 60% of the dose.
Primarily hepatic metabolism via CYP3A4 and CYP1A2, with metabolites excreted in urine (40-50% as metabolites) and feces (40-50% as metabolites). Less than 1% excreted unchanged.
Category C
Category C
Phosphodiesterase-4 Inhibitor
Phosphodiesterase-4 Inhibitor
"Roflumilast may increase the immunosuppressive activities of Cortisone acetate."